TransMedics Group Inc vs Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037 — how do they compare? TransMedics Group Inc trades at $79.31 (market cap $2.74B), while Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037 trades at $45.6 (market cap $311.72M). The key difference: TransMedics Group Inc is far larger — about 8.8× Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037's market cap, and TransMedics Group Inc is more actively traded (949,331 versus 75,888). Which is the better fit depends on your goals — on Pluang, investors hold TransMedics Group Inc for 24 Days and Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037 for 48 Days on average.
| TMDX | USOI | |
|---|---|---|
Market Cap | $2.74B | $311.72M |
Volume | 949,331 | 75,888 |
Sector | Health | Income / Options Overlay |
52-Week High | $150.42 | $61.17 |
52-Week Low | $61.99 | $42.27 |
Typical Hold Time | 24 Days | 48 Days |
Enterprise Value | $3.13B | — |
Signals from Pluang's Aura AI — not financial advice
TransMedics Group (TMDX) trades at $80.69, down 0.47% on the day, amid a bearish technical signal and mixed earnings performance. The company reported strong revenue growth to $605.49M in 2025 with a net income margin of 22.69%, but recent quarters have seen earnings misses. Analyst sentiment remains positive with a consensus price target of $99.75 and a 69% buy rating, though news flow includes investigations into fiduciary duties.
The outlook balances robust fundamentals against near-term headwinds. Upside potential exists from the high analyst target and strong profitability metrics like a 36.28% ROE, but risks include earnings volatility, margin pressure, and ongoing legal scrutiny. The stock's current valuation at a P/E of 20.47 offers a reasonable entry if execution improves.
USOI trades at $44.61, down 0.82% today, with a bearish technical signal driven by moving averages. Support levels are at $44 and $43, while resistance sits at $45 and $46. Financial ratios like P/E and P/S are unavailable in the data, limiting fundamental clarity. Recent portfolio commentary from Seeking Alpha on September 3, 2026, highlighted strategic cash-raising moves, though direct company news is sparse.
The outlook is cautious due to weak technical momentum and absent fundamental metrics. Risks include market volatility and lack of earnings visibility. Investment opportunity hinges on a rebound above resistance, but current sentiment and technicals suggest near-term pressure for stockholders.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →USOI is an Exchange-Traded Note (ETN) issued by UBS that provides exposure to a covered call strategy on the United States Oil Fund (USO). It aims to generate high monthly income by capturing option premiums from the hypothetical sale of out-of-the-money call options on oil shares, offering a way to profit from crude oil's volatility even in a flat or range-bound market.
Read more on USOI →